Table 1. Characteristics of study... | American Society of Hematology

Table 1.

Characteristics of study population (N = 28)

Characteristic	No.
Male	20
Female	8
Hematologic malignancy
Acute lymphoblastic leukemia	5
Chronic myeloid leukemia	14
Acute myelogenous leukemia	6
Myeloma	3
Donor
Sibling	19
Matched unrelated	9
Donor lymphocyte infusion	11
cGVHD disease type
Progressive	9
De novo	14
Relapsed	5
Predictive factors
More than 50% cutaneous involvement	20
Progressive cGVHD	9
Platelet count less than 100 × 10⁹/L	1
No predictive factors	4
1 of 3 predictive factors	17
2 of 3 predictive factors	7
Systemic therapy
Prednisolone/methylprednisolone	26
Cyclosporin	24
Mycophenolate mofetil	7
Thalidomide	5
PUVA	5
Azathioprine	4
Tacrolimus (FK 506)	2
Methotrexate	1
Cyclophosphamide	1
Median delay before starting ECP, mo (range)
From diagnosis	45 (15-193)
From allograft	34 (10-167)
From onset of cGVHD	23 (2-164)

Characteristic	No.
Male	20
Female	8
Hematologic malignancy
Acute lymphoblastic leukemia	5
Chronic myeloid leukemia	14
Acute myelogenous leukemia	6
Myeloma	3
Donor
Sibling	19
Matched unrelated	9
Donor lymphocyte infusion	11
cGVHD disease type
Progressive	9
De novo	14
Relapsed	5
Predictive factors
More than 50% cutaneous involvement	20
Progressive cGVHD	9
Platelet count less than 100 × 10⁹/L	1
No predictive factors	4
1 of 3 predictive factors	17
2 of 3 predictive factors	7
Systemic therapy
Prednisolone/methylprednisolone	26
Cyclosporin	24
Mycophenolate mofetil	7
Thalidomide	5
PUVA	5
Azathioprine	4
Tacrolimus (FK 506)	2
Methotrexate	1
Cyclophosphamide	1
Median delay before starting ECP, mo (range)
From diagnosis	45 (15-193)
From allograft	34 (10-167)
From onset of cGVHD	23 (2-164)